The Use of Bevacizumab in the Treatment of Retinopathy of Prematurity

Int Ophthalmol Clin. 2022 Jan 1;62(1):219-230. doi: 10.1097/IIO.0000000000000400.
No abstract available

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Humans
  • Infant, Newborn
  • Intravitreal Injections
  • Retinopathy of Prematurity* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab